Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation.
The purpose of this study was to develop Cremophor EL-free nanoparticles loaded with Paclitaxel (PTX), intended to be intravenously administered, able to improve the therapeutic index of the drug and devoid of the adverse effects of Cremophor EL. PTX-loaded PEGylated PLGA-based were prepared by simple emulsion and nanoprecipitation. The incorporation efficiency of PTX was higher with the nanoprecipitation technique. The release behavior of PTX exhibited a biphasic pattern characterized by an initial burst release followed by a slower and continuous release. The in vitro anti-tumoral activity was assessed using the Human Cervix Carcinoma cells (HeLa) by the MTT test and was compared to the commercial formulation Taxol and to Cremophor EL. When exposed to 25 microg/ml of PTX, the cell viability was lower for PTX-loaded nanoparticles than for Taxol (IC(50) 5.5 vs 15.5 microg/ml). Flow cytometry studies showed that the cellular uptake of PTX-loaded nanoparticles was concentration and time dependent. Exposure of HeLa cells to Taxol and PTX-loaded nanoparticles induced the same percentage of apoptotic cells. PTX-loaded nanoparticles showed greater tumor growth inhibition effect in vivo on TLT tumor, compared with Taxol. Therefore, PTX-loaded nanoparticles may be considered as an effective anticancer drug delivery system for cancer chemotherapy.
Danhier
Fabienne
F
Université Catholique de Louvain, Unité de Pharmacie Galénique, Avenue Mounier, 73-20, 1200 Brussels, Belgium.
Lecouturier
Nathalie
N
Vroman
Benoît
B
Jérôme
Christine
C
Marchand-Brynaert
Jacqueline
J
Feron
Olivier
O
Préat
Véronique
V
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004337:Drug Carriers / Q000737:chemistry; D004353:Drug Evaluation, Preclinical; D005027:Ethylene Oxide / Q000737:chemistry; D005079:Excipients / Q000494:pharmacology; D005434:Flow Cytometry; D005990:Glycerol / Q000031:analogs & derivatives / Q000494:pharmacology; D006367:HeLa Cells; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry*; D007783:Lactones / Q000737:chemistry; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D053758:Nanoparticles / Q000737:chemistry*; D009369:Neoplasms / Q000188:drug therapy / Q000473:pathology; D017239:Paclitaxel / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D010316:Particle Size; D011092:Polyethylene Glycols / Q000737:chemistry*; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D013501:Surface-Active Agents / Q000494:pharmacology; D016019:Survival Analysis
D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D005079:Excipients; D007783:Lactones; C400421:PLC(20)-b-PEO(44); D013501:Surface-Active Agents; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D011092:Polyethylene Glycols; C000515:cremophor EL; D005027:Ethylene Oxide; D017239:Paclitaxel; D005990:Glycerol